Asymptomatic carriage of Pneumocystis jiroveci in elderly patients with rheumatoid arthritis in Japan: a possible association between colonization and development of Pneumocystis jiroveci pneumonia during low-dose MTX therapy

References

• Pavy S, Constantin A, Pham T, Gossec L, Maillefert JF, Canta-grel A, et al. Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine. 2006;73:388–95.
   Google Scholar
• Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M, et al. EULAR recommendations for the manage-ment of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66:34–45.
   PubMed Web of Science ®Google Scholar
• Buchbinder R, Hall S, Sambrook PN, Champion GD, Harkness A, Lewis D, et al. Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice. J Rheumatol. 1993;20:639–44.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Maier AL, Fraser PA, Coblyn JS. Long-term pro-spective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. J Rheumatol. 1998;25:238–42.
   PubMed Web of Science ®Google Scholar
• Kanik KS, Cash JM. Does methotrexate increase the risk of infection or malignancy? Rheum Dis Clin North Am. 1997;23:955–67.
   Google Scholar
• Boerbooms AM, Kerstens PJ, van Loenhout JW, Mulder J, van de Putte LB. Infections during low-dose methotrexate treatment in rheumatoid arthritis. Semin Arthritis Rheum. 1995;24:411–21.
   Google Scholar
• Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis com-pared with controls: a population-based study. Arthritis Rheum. 2002;46:2287–93.
   Google Scholar
• White DA. Drug-induced pulmonary infection. Clin Chest Med. 2004;25:179–87.
   PubMedGoogle Scholar
• Segal R, Yaron M, Tartakovsky B. Methotrexate: mechanism of action in rheumatoid arthritis. Semin Arthritis Rheum. 1990;20: 190–200.
   Google Scholar
• Roblot F, Godet C, Le Moal G, Garo B, Faouzi Souala M, Dary M, et al. Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immuno-compromised HIV-negative patients. Eur J Clin Microbiol Infect Dis. 2002;21:523–31.
   PubMed Web of Science ®Google Scholar
• Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc. 1996;71:5–13.
   PubMed Web of Science ®Google Scholar
• Sepkowitz KA. Pneumocystis carinii pneumonia in patients without AIDS. Clin Infect Dis. 1993;17(Suppl 2):5416–22.
   Google Scholar
• Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Post-marketing surveillance of the safety profile of infliximab in 5,000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2007;67:189–94.
   PubMedGoogle Scholar
• Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis. 2002;8:891–6.
   PubMed Web of Science ®Google Scholar
• Wakefield AE, Pixley FJ, Banerji S, Sinclair K, Miller RF, Mo-xon ER, et al. Detection of Pneumocystis carinii with DNA amplification. Lancet. 1990;336:451–3.
   Google Scholar
• Miller RF, Ambrose HE, Wakefield AE. Pneumocystis carinii f. sp. hominis DNA in immunocompetent health care workers in contact with patients with P. carinii pneumonia. J Clin Microbiol. 2001;39:3877–82.
   Google Scholar
• Miller RF, Lindley AR, Copas A, Ambrose HE, Davies RJ, Wakefield AE. Genotypic variation in Pneumocystis jiroveci isolates in Britain. Thorax. 2005;60:679–82.
   PubMedGoogle Scholar
• Ihata A, Soga T, Takemura S, Fujita H. A case of Pneumocystis pneumonia associated with rheumatoid arthritis. Shizuoka Se-kijyuji Byoin Kenkyuhou. 2002;22:67–71.
   Google Scholar
• Nakashima A, Toufuku Y, Ojima T. Seventy one year-old female patient with rheumatoid arthritis developed Pneumocystis carinii pneumonia mimicking methotrexate pneumonitis. J Chubu Rheum Assoc. 2005;36:74–5.
   Google Scholar
• Jojima H, Naito M, Shiraishi M, Matsumoto T, Noritomi T, Hayashi H. Pneumocystis carinii pneumonia and perforation of the colon in a patient with rheumatoid arthritis receiving low dose methotrexate and glucocorticoid hormone. Kyushu J Rheumatol. 2005;25:30–4.
   Google Scholar
• Kawagishi Y, Yamaguchi T, Matsui S, Narukawa M, Fujita T, Oda H, et al. A case of Pneumocystis pneumonia misidentified as methotrexate-induced pneumonitis. J Jap Respir Soc. 2005;43: 486–90.
   Google Scholar
• Kaneko Y, Suwa A, Ikeda Y, Hirakata M. Pneumocystis jiroveci pneumonia associated with low-dose methotrexate treatment for rheumatoid arthritis: report of two cases and review of the liter-ature. Mod Rheumatol. 2006;16:36–8.
   PubMedGoogle Scholar
• Ohashi H, Izui Y, Kondo M, Saito M, Suzuki D. Pneumocystis carinii pneumonia treated with low dose methotrexate pulse therapy for rheumatoid arthritis: four cases report. J Chubu Rheum Assoc. 2006;37:26–7.
   Google Scholar
• Kitsuwa S, Matsunaga K, Kawai M, Tsuzi T, Kato K, Tani K, et al. Pancytopenia and Pneumocystis carinii pneumonia associ-ated with low dose methotrexate pulse therapy for rheumatoid arthritis-case report and review of literature. Ryumachi. 1996;36: 551–8.
   PubMedGoogle Scholar
• Okuda Y, Oyama T, Oyama H, Miyamoto T, Takasugi K. Pneumocystis carinii pneumonia associated with low dose methotrexate treatment for malignant rheumatoid arthritis. Ryu-machi. 1995;35:699–704.
   Google Scholar
• Shoda H, Inokuma S, Yajima N, Tanaka Y, Setoguchi K. Two cases of rheumatoid arthritis presenting lung injury during low dose methotrexate pulse therapy. Kanto Ryumachi. 2005;38: 78–88.
   Google Scholar
• Shimada T, Nishimura Y, Funada Y, Takenaka K, Kobayashi K, Urata Y, et al. A case of pneumocystis carinii pneumonia asso-ciated with low dose methotrexate treatment for rheumatoid arthritis and trimethoprim-sulfamethoxazole induced pancytope-nia. Arerugi. 2004;53:575–81.
   PubMedGoogle Scholar
• Saketkoo LA, Espinoza LR. Impact of biologic agents on infec-tious diseases. Infect Dis Clin North Am. 2006;20:931-61, viii.
   Google Scholar
• Yasuoka A, Tachikawa N, Shimada K, Kimura S, Oka S. (1-3) beta-D-glucan as a quantitative serological marker for Pneumocystis carinii pneumonia. Clin Diagn Lab Immunol. 1996;3: 197–9.
   Google Scholar
• Sing A, Roggenkamp A, Autenrieth IB, Heesemann J. Pneumo-cystis carinii carriage in immunocompetent patients with primary pulmonary disorders as detected by single or nested PCR. J Clin Microbiol. 1999;37:3409–10.
   PubMed Web of Science ®Google Scholar
• Calderon EJ, Regordan C, Medrano FJ, 011ero M, Varela JM. Pneumocystis carinii infection in patients with chronic bronchial disease. Lancet. 1996;347:977.
   Google Scholar
• Armbruster C, Hassl A, Kriwanek S. Pneumocystis carinii colo-nization in the absence of immunosuppression. Scand J Infect Dis. 1997;29:591–3.
   Google Scholar
• Nevez G, Raccurt C, Jounieaux V, Dei-Cas E, Mazars E. Pneu-mocystosis versus pulmonary Pneumocystis carinii colonization in HIV-negative and HIV-positive patients. AIDS. 1999;13: 535–6.
   Google Scholar
• Maskell NA, Waine DJ, Lindley A, Pepperell JC, Wakefield AE, Miller RF, et al. Asymptomatic carriage of Pneumocystis jiroveci in subjects undergoing bronchoscopy: a prospective study. Tho-rax. 2003;58:594–7.
   PubMed Web of Science ®Google Scholar
• Harigai M, Koike R, Miyasaka N. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med. 2007;357: 1874–6.
   Google Scholar
• Mori S, Imamura F, Kiyofuji C, Ito K, Koga Y, Honda I, et al. Pneumocystis jiroveci pneumonia in a patient with rheumatoid arthritis as a complication of treatment with infliximab, anti-tumor necrosis factor alpha neutralizing antibody. Mod Rheu-matol. 2006;16:58–62.
   PubMedGoogle Scholar
• Koetz K, Bryl E, Spickschen K, O'Fallon WM, Goronzy JJ, Weyand CM. T cell homeostasis in patients with rheumatoid arthritis. Proc Natl Acad Sci USA. 2000;97:9203–8.
   PubMed Web of Science ®Google Scholar
• Wagner UG, Koetz K, Weyand CM, Goronzy JJ. Perturbation of the T cell repertoire in rheumatoid arthritis. Proc Natl Acad Sci USA. 1998;95:14447–52.
   PubMed Web of Science ®Google Scholar
• Vallejo AN. Age-dependent alterations of the T cell repertoire and functional diversity of T cells of the aged. Immunol Res. 2006;36:221–8.
   PubMed Web of Science ®Google Scholar
• Takayanagi NTY, Tokunaga D, Miyahara Y, Yamaguchi S, Saito H, Ubukata M, et al. Pulmonary infections in patients with rheumatoid arthritis. J Jap Respir Soc. 2007;45:465–73.
   Google Scholar
• Iikuni N, Kitahama M, Ohta S, Okamoto H, Kamatani N, Nish-inarita M. Evaluation of Pneumocystis pneumonia infection risk factors in patients with connective tissue disease. Mod Rheu-matol. 2006;16:282–8.
   Google Scholar
• LeMense GP, Sohn SA. Opportunistic infection during treatment with low dose methotrexate. Am J Respir Crit Care Med. 1994;150:258–60.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associa-tions with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006;54: 628–34.
   Google Scholar
• Kirwan JR, Bijlsma JW, Boers M, Shea BJ. Effects of gluco-corticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev. 2007:CD006356.
   Google Scholar
• Hashimoto H. Prophylaxis of Pneumocystis jiroveci pneumonia in autoimmune disease (in Japanese). Tokyo: Japanese Ministry of Health, Labor and Welfare Study Group on complication and treatment of immune disease. 2005:14–9.
   Google Scholar